Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMEDIATE pilot study of early intravenous immunoglobulin in newly diagnosed idiopathic inflammatory myopathies
NL-OMON46904Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of immune globulin in Autoimmune Myopathies, dermatomyositis (DM), antisynthetase syndrome (ASSD) and 2 more (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Clinically significant improvement at 9 weeks. Started Apr 2017; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)Myositis
Beyond the preview
Go deeper on NL-OMON46904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46904.